YM BioSciences (YM.TO) Reports Daiichi Sankyo Co Ltd. and Kuhnil Pharmaceutical Company Enrol First Patients in Randomized Phase II Gastric Trial
10/1/2008 3:41:30 PM
More...
|
YM BioSciences (YM.TO) Expands Development Program For EGFR Inhibitor Nimotuzumab; Partners With Kuhnil Pharmaceutical Company To Develop Nimotuzumab (TheraCIM-hR3) For Non-Small Cell Lung Cancer
10/19/2005 5:08:55 PM
More...
|